AstraZeneca faces Losec investigation
The world's biggest selling drug is under attack on both sides of the Atlantic as its patent expiry looms. AstraZeneca, maker of Losec, has been accused of breaching European competition rules, and is also facing litigation to stop US companies bringing out generic versions of the drug.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
